Plain-English translation of NCT04022616 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →This research study is looking at special immune cells called myeloid-derived suppressor cells in people with breast cancer. Researchers want to understand how these cells function and whether they play a role in how well cancer treatments work. By studying these cells in patients at different stages of treatment, scientists hope to gain insights that could improve future breast cancer care.
Doctors and researchers believe that understanding how certain immune cells behave in breast cancer may help explain why some treatments work better than others. This knowledge could eventually lead to new or improved ways to treat the disease.
You likely qualify if…
You likely don't qualify if…
Depending on which group you join, you may have blood drawn before and after your cancer treatment, or tissue samples collected during your surgery. Some participants will provide samples before starting chemotherapy, others during surgery, and some with advanced cancer will provide samples when starting a new treatment. The study involves working with your cancer care team to collect these samples at appointments you're already having for your standard cancer care.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States
Enrollment target
~99 participants
Started
June 2010
Primary completion
December 2027
Age range
18 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ohio State Comprehensive Cancer Center
Ohio State Comprehensive Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.